Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs High-dose Radioiodine Ablation in Intermediate-risk Papillary Thyroid Carcinoma
NCT04354324Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of iodine-131 in Papillary Thyroid Carcinoma (PTC) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Disease-Free Survival at 3 years. Started Apr 2020; status: recruiting.
02
Drugs
iodine-131
03
Conditions
Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT04354324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354324.